Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 390 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ZILRETTA Clear all

Conditions: Delayed Graft Function
Interventions: Everolimus, Tacrolimus, Mycophenolate mofetil (MMF/MPA); Drug
Lead sponsor: Matthew Cooper; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Tibial Meniscus Injuries, Tibial Meniscus Tears, Tibial Meniscus, Torn, Anterior Cruciate Ligament Tear
Interventions: Zilretta, Placebo; Drug · Other
Lead sponsor: Austin V Stone; Other
Eligibility: 18 Years to 40 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Diabetic Macular Edema
Interventions: IVT Aflibercept, SC CLS-TA; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Mountain View, California • The Woodlands, Texas

Conditions: Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Ranibizumab, Triamcinolone Acetonide, Sham injection, Focal/grid laser; Drug · Behavioral · Procedure
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 56
States / cities: Artesia, California • Beverly Hills, California • Irvine, California + 46 more

Conditions: Skin Inflammation, Allergic Contact Dermatitis
Interventions: Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab, Adalimumab, Ustekinumab, Guselkumab, Canakinumab, Sarilumab, Triamcinolone Acetonide, Betamethasone Valerate, Fluticasone Propionate, Microneedle, Suction blistering, Skin punch biopsy; Drug · Other · Device + 1 more
Lead sponsor: Wei-Che Ko; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Nasal Obstruction
Interventions: Triamcinolone Acetonide, Ayr saline nasal mist; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hand Dermatoses
Interventions: Triamcinolone Acetonide (TAC) DuraPeel, Placebo DuraPeel; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 3
States / cities: San Diego, California • Clinton Township, Michigan • Austin, Texas

Conditions: Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Anterior, Panuveitis, Uveitis, Intermediate
Interventions: 4 mg CLS-TA, 0.8 mg CLS-TA; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 11
States / cities: Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more

Conditions: Sinusitis
Interventions: Stratus Microflow Ethmoid Spacer; Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 17 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Volume Loss to Dorsum of Hands
Interventions: Calcium Hydroxylapatite and Triamcinolone acetate, Calcium Hydroxylapatite and Placebo; Other · Device
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 22 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Breast Cancer
Interventions: Docetaxel,doxorubicin, cyclophosphamide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 3,299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Graft-versus-host-disease, GVHD, GVHD, Acute
Interventions: BMS-986004, Sirolimus, Tacrolimus; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Duarte, California • Tampa, Florida • Columbus, Ohio

Conditions: Osteoarthritis of the Shoulder, Osteoarthritis of the Hip
Interventions: FX006 32 mg, TAcs 40 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: El Cajon, California • La Mesa, California • San Diego, California + 3 more

Conditions: Fibromatosis
Interventions: Triamcinolone Acetonide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 89 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Dental Pain, Postoperative Pain
Interventions: benzocaine, TAC alternate gel; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: 6655 Travis Suite 460, Texas

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Immunosuppressant Regimen; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more

Conditions: Hematologic Malignancy
Interventions: Abatacept; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Postoperative Ocular Inflammation, Postoperative Ocular Pain
Interventions: Sham (No Treatment), TRIESENCE (triamcinolone acetonide injectable suspension); Procedure · Drug
Lead sponsor: Harrow Inc; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Tennis Elbow, Lateral Epicondylitis
Interventions: Placebo Injection, Physical Therapy, Corticosteroid Injections, Prolotherapy; Drug · Behavioral
Lead sponsor: Christine M. Kleinert Institute for Hand and Microsurgery; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Renal Transplant Rejection
Interventions: Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy; Drug · Other · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Leukemia, Lymphocytic, Chronic
Interventions: LMB-2; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoarthritis, Knee, Knee Pain
Interventions: Micro Fragmented Adipose Tissue, Corticosteroid injection; Biological
Lead sponsor: Stanford University; Other
Eligibility: 35 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Osteoarthritis of the Knee
Interventions: FX006 32 mg, Placebo, FX006 16 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 39
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 36 more

Conditions: Pancreatitis, Chronic, Pancreatitis
Interventions: Celiac Block with triamcinolone and bupivicaine, No Celiac Block, Intra Plexus Triamcinolone and Bupivicaine Injection; Procedure · Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury

Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation

Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis

Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide

A Single-Center Investigator-Initiated Evaluator-Bilateral-Comparison Pilot Study of Injectable Calcium Hydroxylapatite With and Without Triamcinolone Acetate for the Treatment of Volume Loss to Dorsum Areas of the Hands

Docetaxel in Breast Cancer

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors

Comparative Efficacy of 20% Benzocaine Versus TAC Alternate Gel

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT

A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery

Comparison of Conservative Methods for the Treatment of Lateral Epicondylitis: A Randomized, Prospective Study

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

The Effect of Micro Fragmented Adipose Tissue (MFAT) on Knee Osteoarthritis

Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee

Celiac Plexus Block for Chronic Pancreatitis RCT